Fennec Pharmaceuticals Inc. Common Stock

Day range

$9.98 – $10.27

Open

$10.08

Prev close

$10.08

Volume

52.03K

Market cap

$353.48M

Shares out

35.14M

P/E

—

P/S

5.97

P/B

8.33

P/FCF

—

ROE

-7.7%

ROA

-4.3%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsSep 17, 2026

  On September 17, 2026, Fennec Pharmaceuticals Inc. (the "Company") announced positive results from the investigator-initiated Phase 2 STS-J01 clinical study of PEDMARK® in Japan, which met its primary endpoint and demonstrated significant hearing protection without evidence of interference with cisplatin antitumor activity.

• Annual meeting resultsJun 10, 2026

  On June 10, 2026, Fennec Pharmaceuticals Inc. (the "Company") held an annual meeting of shareholders (the "Meeting"). The shareholders approved all proposals considered at the Meeting and approved all nominees of the Company for director.

• Equity compensation grantMay 18, 2026

  On May 11, 2026, the Compensation Committee of the Board of Directors of Fennec Pharmaceuticals Inc. approved grants of stock options to purchase an aggregate of 50,000 common shares to three new employees under the Company's 2026 Equity Inducement Plan, with a grant date of May 18, 2026, as inducement awards pursuant to Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.75 per share, a ten-year term and vest over three years, with one-third vesting on the first anniversary of the grant date and the balance vesting monthly over the following 24 months, subject to continued employment.

• Director departureApr 28, 2026

  On April 27, 2026, Rostislav Raykov notified Fennec Pharmaceuticals Inc. (the "Company") of his desire to retire from the Company's Board of Directors (the "Board") and that he will not stand for re-election at the Company's 2026 annual meeting of shareholders (the "Annual Meeting").

• Settlement agreementMar 16, 2026

  On March 16, 2026, Fennec Pharmaceuticals Inc. (the "Company") entered into a License Agreement with Cipla Limited and Cipla USA, Inc. (together, "Cipla") to resolve the litigation between the Company and Cipla relating to Cipla's application to the U.S. Food and Drug Administration to market a generic version of the Company's PEDMARK® (sodium thiosulfate injection) product... Pursuant to the terms of the License Agreement, the lawsuit will be dismissed, each party will bear its own costs in connection with the litigation, and Cipla has agreed not to enter the U.S. market with its generic sodium thiosulfate product until September 1, 2033, subject to earlier entry under specified circumstances.

Days to cover

3.9

Short interest

513.29K

Avg volume

133.17K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
  neutralGlobeNewswire Inc.· Dec 26, 2025
• Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
  neutralGlobeNewswire Inc.· Nov 13, 2025
• Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares
  neutralGlobeNewswire Inc.· Nov 13, 2025
• Fennec Q2 Sales Jump 33 Percent
  positiveThe Motley Fool· Aug 14, 2025
• Fennec Announces Results of Annual Meeting
  positiveGlobeNewswire Inc.· Jun 3, 2025